Lipiodol Ultra-Fluid

Ethiodized oil, the active ingredient in Lipiodol Ultra-Fluid, is an iodinated oil-based contrast media presented as a liquid for intra-arterial, intralymphatic and intramuscular use. It provides radiopaque contrast that enhances X-ray visualization of vascular and lymphatic structures, supporting diagnostic imaging and therapeutic embolization procedures.

GNH USA supplies Lipiodol Ultra-Fluid as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and imaging clinics worldwide. The company ensures quality compliance with EU standards and reliable global distribution.

Lipiodol Ultra-Fluid, an iodinated oil-based contrast agent, is employed in radiographic procedures that require detailed visualization of vascular, lymphatic and hepatobiliary systems.

- Lymphangiography: enables high-resolution imaging of lymphatic vessels and nodes for diagnostic assessment. - Hepatobiliary imaging: provides selective opacification of the biliary tree to evaluate liver and gallbladder disorders. - Tumor embolization and chemoembolization: serves as a carrier for embolic particles or chemotherapeutic agents to occlude tumor blood supply and enhance local drug delivery.

Adverse reactions to Lipiodol Ultra-Fluid are generally related to its iodine content and oil vehicle.

Common Side Effects: - Injection site pain or burning sensation. - Transient fever or chills. - Nausea or mild vomiting. - Headache. - Mild skin rash or urticaria. - Temporary thyroid function changes (subclinical hyper- or hypothyroidism).

Serious or Rare Side Effects: - Severe allergic reaction or anaphylaxis. - Pulmonary embolism from oil migration. - Acute renal impairment, especially in patients with pre-existing kidney disease. - Significant thyroid dysfunction (iodine-induced thyrotoxicosis or hypothyroidism). - Vascular occlusion leading to tissue necrosis. - Cardiovascular collapse or hypotension.

Prior to using Lipiodol Ultra-Fluid, clinicians should evaluate patient history and clinical status to minimize risks.

- Allergy assessment: confirm no known iodine or oil‑based contrast allergy. - Thyroid evaluation: assess baseline thyroid function in patients with thyroid disease. - Renal function: check kidney function, especially in those with chronic renal insufficiency. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks, as safety data are limited. - Concomitant therapies: use caution with radioactive iodine treatment or thyroid hormone replacement. - Monitoring: observe patients for immediate hypersensitivity reactions during and after administration. - Store at ambient temperature: keep in original container, protect from light and moisture.

Lipiodol Ultra-Fluid may interact with certain medications or therapies that affect iodine handling or organ function.

Major Interactions (Avoid): - Radioactive iodine therapy: excess iodine can diminish therapeutic efficacy. - Thyroid hormone replacement (levothyroxine) or antithyroid drugs: may precipitate thyroid dysfunction. - Nephrotoxic agents (e.g., aminoglycosides, amphotericin B): increase risk of renal impairment.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask tachycardia associated with contrast reactions. - Diuretics: can alter fluid balance during intra‑arterial administration. - Corticosteroids: may reduce severity of allergic responses, requiring dose adjustment. - ACE inhibitors: monitor blood pressure as contrast may potentiate hypotensive effects.